Internal Reference Number: FOI_9196
Date Request Received: 29/01/2026 00:00:00
Date Request Replied To: 10/02/2026 00:00:00
This response was sent via: By Email
Request Summary: Dravet syndrome and Lennox鈥揋astaut syndrome
Request Category: Companies
| Question Number 1: For all questions, patient numbers should represent unique patients within the specified reporting period. Where a monthly breakdown is not available, please provide unique patient numbers aggregated by quarter instead. The number of patients under the trust鈥檚 care with a recorded diagnosis of Dravet syndrome in each month of 2025 (January鈥揇ecember). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.3 or SNOMED code 230437002. a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ | |
| Answer To Question 1: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. To accompany this answer to question 1 please also see the documents listed below:  13495 - FOI_9196 - Dravet syndrome and Lennox鈥揋astaut syndrome FOR ISSUE.xlsx | |
| Question Number 2: 2. The number of patients under the trust鈥檚 care with a recorded diagnosis of Lennox-Gastaut syndrome in each month of 2025 (January-December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006. a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ | |
| Answer To Question 2: Please see our response to all questions in the spreadsheet attached. | |
| Question Number 3: 3. The number of patients under the trust鈥檚 care who have been treated with fenfluramine in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox鈥揋astaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication | |
| Answer To Question 3: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. | |
| Question Number 4: 4. The number of patients under the trust鈥檚 care who have been treated with cannabidiol in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox鈥揋astaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. | |
| Answer To Question 4: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. | |
| Question Number 5: 5. The number of patients under the trust鈥檚 care who have been treated with cenobamate in in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox鈥揋astaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. | |
| Answer To Question 5: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. | |
| Question Number 6: 6. The number of patients under the trust鈥檚 care who have been treated with rufinamide in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Lennox鈥揋astaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. | |
| Answer To Question 6: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. | |
| Question Number 7: 7. The number of patients under the trust鈥檚 care who have been treated with stiripentol in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox鈥揋astaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. | |
| Answer To Question 7: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. | |
| Question Number 8: 8. The number of patients under the trust鈥檚 care who have been treated with clobazam in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox鈥揋astaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. | |
| Answer To Question 8: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. | |
| Question Number 9: 9. The number of patients under the trust鈥檚 care who have been treated with sodium valproate in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox鈥揋astaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. | |
| Answer To Question 9: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. | |
| Question Number 10: The number of patients under the trust鈥檚 care who have been treated with topiramate in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox鈥揋astaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. | |
| Answer To Question 10: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. | |
| Question Number 11: . The number of patients under the trust鈥檚 care who have been treated with lamotrigine in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Lennox鈥揋astaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. | |
| Answer To Question 11: Please see our response to all questions in the spreadsheet attached. Please note, for questions 3-11 we are unable to answer parts c or d as we were unable to search for "other anti-seizure medications" as this was too broad. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
